Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2004

View Archived Issues

Procyon makes good progress with three main programs during Q1

AMD-3100 improves the eligibility of MM patients for stem cell transplantation

Therapeutic benefits of AVR-118 in cachectic AIDS and cancer patients

DOV updates recent progress

Novel class of nucleoside analogues against hepatitis B virus

Cambridge Biotechnology raises funds to advance product candidates

DOR BioPharma and Jefferson enter CRADA for botulinum toxin vaccines

ExonHit develops improved formulation of Ikomio

PK/PD modeling and clinical trial simulation for preparation of dabigatran phase III trials

New data on the population pharmacokinetics of fosfluconazole and fluconazole

Clinical data support the use of the anti-IL-6R antibody MRA in rheumatoid arthritis

Update on the safety and efficacy of LJP-394 in SLE

Therapeutic benefits of rimonabant in obese subjects and a preclinical model of obesity

New antimicrobial cephems described by Fuijsawa and Wakunaga scientists

Another series of antibacterial aminopeptidase inhibitors reported by Procter & Gamble

5-HT reuptake inhibitors and 5-HT receptor agonists developed at Merck KGaA

Novel GABA-A receptor ligands in early development at Neurogen

Four series of chemokine CCR2 modulators and their use in arthritis and other disorders

New iNOS inhibitors claimed for use in arthritis, IBD, pain, etc.

Novel glycogen phosphorylase inhibitors under study at Pfizer

Phase I trial for Pevion's new malaria vaccine

Sativex improves spasticity in MS patients in phase III trial

European approval for Watson's oxybutynin transdermal product

Tipranavir Compassionate Use Program expanded

Telmisartan provides superior blood pressure control to valsartan and amlodipine

AGT Biosciences and ChemGenex Therapeutics complete merger

Panvac-VF enters phase III trial for pancreatic cancer

Cardioprotective effects of angiotensin II type 2 receptor gene transfer

Studies support further investigation of T-131 in type 2 diabetes

Recent pregabalin study results presented at epilepsy congress

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...